徐小博;楚慧丽;毕经旺;王洪娜;徐志香;王俊;

• 1:中国人民解放军济南军区总医院肿瘤科

摘要(Abstract)：

个体化治疗(Personalized Medicine)是指通过患者体内的有关药物作用靶点、路径、代谢等靶标,评估药物对患者可能的作用,提高治疗的针对性、避免反复尝试与不良反应,提高用药的安全性和有效性。目前对胃癌个体化治疗研究最多,最能被临床所接受及认识的就是——通过药物敏感性基因检测,实现对胃癌化疗药物敏感性和疗效预测。

关键词(KeyWords)： 基因检测;胃癌;治疗

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金资助项目(No.30901788)

作者(Author): 徐小博;楚慧丽;毕经旺;王洪娜;徐志香;王俊;

Email:

DOI:

参考文献(References)：

• [1]Brenner H,Rothenbacher D,Arndt V.Epidemiology of stomach cancer[J].Methods Mol Biol,2009,472:467-477.
• [2]Comis RL,Carter SK.A review of chemotherapy in gastric cancer[J].Cancer,1974,34(5):1576-1586.
• [3]Koizumi W,Kurihara M,Nakano S,et al.Phase II study of S-1,a novel oral derivative of5-fluorouracil,in advanced gastric cancer[J].On-cology,2000,58(3):191-197.
• [4]Jin M,Shen L,Hu B,et al.Mature data on capecitabine(X)+fractionated cisplatin(P)as first-line therapy in patients(pts)with advanced gastric carcinoma(AGC)[J].Journal of Clinical Oncology,2006,24(18-sup-pl):4075.
• [5]Jperger M,Omlin A,Cerny T,Fruh M.The role of pemetrexed in advanced non small-cell lung cancer::special focus on pharmacology and mechanism of action[J].Curr DrugTargets.2010;11(1):37-47.
• [6]Abolmaali K,Balakrishnan A,Steams AT,et al.Circadian varia-tion in intestinal dihydropyrimideine dehydrogenase(DPD)expression:a potential mechanism for benefits of5FU chrono-chemotherapy[J].Sur-gery,2009;146(2):269-273.
• [7]Hoffmann AC,Brabender J,Metzger R,et al.Dihydropyrimi-deine dehydrogenase mRNA expression in peripheral blood of rectal can-cer patients is significantly associated with residual tumor and distant metas-tases following resection[J].J Surg Oncol,2009,99(5):296-301.
• [8]Qin B,Tanaka R,Shibata Y,et al.In-vitro schedule-dependent interaction between oxaliplatin and5-fluorouracil in human gastric cancer cell line[sJ].Anti-cancer drugs,2006,17(4):445.
• [9]De V F,Orditura M,Matano E,et al.A phase II study of biweek-ly oxaliplatin plus infusional5-fluorouracil and folinic acid(FOLFOX-4)as first-line treatment of advanced gastric cancer patient[sJ].British journal of cancer,2005,92(9):1644-1649.
• [10]Cao W,Yang W,Lou G,et al.Phase II trial of infusional fluoro-uracil,leucovorin,oxaliplatin,and irinotecan(FOLFOXIRI)as first-line treatment for advanced gastric cancer[J].Anti-cancer drugs,2009,20(4):287.
• [11]Edwards J.Src kinase inhibitors:an emerging therapeutic treat-ment option for prostate cancer[J].Expert Opinion on Investigational Drugs,2010,19(5):605-614.
• [12]Quinn J E,James C R,Stewart G E,et al.BRCA1mRNA ex-pression levels predict for overall survival in ovarian cancer after chemo-therapy[J].Clinical Cancer Research,2007,13(24):7413-7420.
• [13]Bepler G,Kusmartseva I,Sharma S,et al.RRM1modulated in vitro and in vivo efficacy of gemcitabine and platinum in non–small-cell lung cance[rJ].Journal of clinical oncology,2006,24(29):4731-4737.
• [14]NCCN Clinical Practice Guidelines in Oncology for NSCLC[M].V2,2009.
• [15]Quinn J E,James C R,Stewart G E,et al.BRCA1mRNA ex-pression levels predict for overall survival in ovarian cancer after chemo-therapy[J].Clinical Cancer Research,2007,13(24):7413-7420.
• [16]Gadgeel S M,Shields A F,Heilbrun L K,et al.Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer[J].American journal of clinical oncology,2003,26(1):37.
• [17]Kii T,Takiuchi H,Gotoh M,et al.Weekly administration regi-men of paclitaxel(PTX)in patient with inoperable or recurrent gastric can-ce[rJ].Gan to kagaku ryōhō,2006,33(5):621-624.
• [18]Taguchi T,Sakata Y,Kanamaru R,et al.Late phase II clinical study of RP56976(docetaxel)in patients with advanced/recurrent gastric cancer:a Japanese Cooperative Study Group trial(group A)[J].Gan to kagaku ryoho.Cancer&chemotherapy,1998,25(12):1915-1924.
• [19]Amarantidis K,Xenidis N,Chelis L,et al.Docetaxel plus oxali-platin in combination with capecitabine as first line treatment for advanced gastric cancer[J].Oncology,2011,80(5-6):359-365.
• [20]Seve P,Mackey J,Isaac S,et al.Class IIIβ-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel[J].Molecular cancer therapeutics,2005,4(12):2001-2007.
• [21]Rosell R,Scagliotti G,Danenberg K D,et al.Transcripts in pre-treatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cance[rJ].Oncogene,2003,22(23):3548-3553.
• [22]Seve P,Dumontet C.Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?[J].Lancet Oncol,2008,9(2):168-175.
• [23]Seve P,Isaac S,Tr O,et al.Expression of Class IIIβ-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy[J].Clinical cancer research,2005,11(15):5481-5486.
• [24]Alli E,Bash-babula J,Yang J M,et al.Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer[J].Cancer re-search,2002,62(23):6864-6689.
• [25]Rosell R,Scagliotti G,Danenberg K D,et al.Transcripts in pre-treatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cance[rJ].Oncogene,2003,22(23):3548-3553.
• [26]Kouzu Y,Uzawa K,Koike H,et al.Overexpression of stathmin in oral squamous-cell carcinoma:correlation with tumour progression and poor prognosi[sJ].British journal of cancer,2006,94(5):717-723.
• [27]Wei S H,Lin F,Wang X,et al.Prognostic significance of stath-min expression in correlation with metastasis and clinicopathological char-acteristics in human ovarian carcinoma[J].Acta Histochemica,2008,110(1):59-65.
• [28]马军,秦叔逵,张清媛.中国临床肿瘤学教育专辑[M].哈尔滨:黑龙江科学技术出版社,2007.296-301.
• [29]Baek J H,Kim J G,Jeon S B,et al.Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cance[rJ].British journal of cancer,2006,94(10):1407-1411.
• [30]Bajetta E,Verzoni E,Ferrario E,et al.Feasibility study of bi-weekly capecitabine,oxaliplatin,and irinotecan in patients with untreated advanced gastric cancer[J].Tumori,2009,95(1):43-47.
• [31]Oh SC,Sur HY,Sung HJ,et al.A phaseⅡshudy of biweekly dose-intensified oral capecitabine plus irinotecan(bXELIRI)for patients with advanced or metastatic gastric cance[J].Br J Cancer,2007,96(10):1514-1519.
• [32]陈亚楠,左云,陆景峰.伊立替康联合CF和5-Fu方案治疗晚期胃癌的临床观察[J].中国肿瘤临床与康复,2011,5(18):422-424.
• [33]Yilmaz U,Oztop I,Alacacioglu A,et al.Irinotecan combined with infusional5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy[J].Chemo-therapy,2006,52(5):264-270.
• [34]Innocenti F,Undevia S D,Iyer L,et al.Genetic variants in the UDP-glucuronosyltransferase1A1gene predict the risk of severe neutro-penia of irinotecan[J].J Clin Oncol,2004,22(8):1382-1388.
• [35]Enzinger Pc,Burtness B,Hollis D E A.CALGB80403/ECOG 1206:a randomized phase II study of three standard chemotherapy regi-mens(ECF,IC,FOLFOX)plus cetuximab in metastatic esophageal and GE junction cance[rJ].ASCO,2010.
• [36]Jo JC,Lee JL,Ryu MH,et al.Phase II and UGT1A1genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer[J].British Journal of Cancer,2012,106:1591-1597.
• [37]Kim MA,Lee HS,Lee HE.EGFR in gastric carcinomas:prog-nostic significance of protein overexpression and high gene copy number[J].Histopathology,2008,52:738-746.
• [38]Doi T,Koizumi W,Siena S,et al.Efficacy,tolerability and phar-macokinetics of gefitinib(ZD1S39)in pretreated patients with metastatic gastric cancer[abstract l036].Proc Am Soc Clin Oncol,2003,22:23S.
• [39]Adelstein DJ,Rybicki LA,Carrol M,et al.Phase II trial of gefi-tinib for recurrent or metastatic esophageal or gastroesphageal junction(GEJ)cance[rJ].Proc Gastrointest Am Soc Clin Oncol Symp,2003,S3:A3.
• [40]Dragovich T,McCoy S,Fenoglio-Preiser CM,et al.Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas:SWOG0127[J].J Clin Oncol,2006,24:4922-4927.
• [41]Pinto C,Di Fabio F,Siena S,et al.Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma(FOLCETUX study)[J].Ann Oncol,2007,18(3):510-517.
• [42]Han SW,Oh DY,Im SA,et al.Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6in advanced gastric cancer[J].Br J Cancer,2009,100:298-304.
• [43]W E.Gastric cancer–ASCO2010[J].memo-Magazine of Eu-ropean Medical Oncology,2010,3(4):168-170.
• [44]Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase3,open-label,randomised controlled trial[J].Lancet,2010,376:687-697.
• [45]Shah M A,Ramanathan R K,Ilson D H,et al.Multicenter phase II study of irinotecan,cisplatin,and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma[J].J Clin Oncol,2006,24(33):5201-5206.
• [46]El-Rayes BF,Zalupski M,Bekai-Saab T,et al.A phase II study of bevacizumab,oxaliplatin,and docetaxel in locally advanced and meta-static gastric and gastroesophageal junction cancers[J].Ann Oncol,2010,21:1999-2004.
• [47]Ohtsu A,Shah MA,Van Cutsem E,et al.Bevacizumab in com-bination with chemotherapy as first-line therapy in advanced gastric can-cer:a randomized,double-blind,placebo-controlled phase III study[J].J Clin Oncol,2011,29:3968-3976.
• [48]Lushnikova AA,Nasunova IB,Parokonnaya AA,et al.VEG-FR-2expression in tumor tissue of breast cancer patients[J].2010,434:363-367.